Dihexa for PTSD & Complex PTSD: Fear Extinction, BDNF & the 2026 UK Review

Around 1 in 20 UK adults — roughly 4.4% — meet diagnostic criteria for post-traumatic stress disorder at any one time, with lifetime prevalence considerably higher. A separate, often-overlapping diagnostic category — ICD-11 complex PTSD (CPTSD), now embedded in NHS clinical practice — affects an estimated 6.2% of people globally on the 2025 pooled meta-analysis, rising to 12.4% in nationally representative community samples and 44.7% in trauma-specialised clinical settings. Among UK veterans deployed in combat roles the rate is about 17%, and a 2024 NHS Op COURAGE evaluation reported that 96% of veterans attending the high-intensity service rated it positively with clinically significant symptom reductions on exit. At the neuroscience level, PTSD has been reframed in the last fifteen years as a disorder of impaired fear extinction: the amygdala holds the conditioned fear response, and the ventromedial prefrontal cortex (vmPFC) / infralimbic cortex normally inhibits the amygdala when extinction learning succeeds. The 2010 Peters et al. paper in Science demonstrated that direct infralimbic BDNF infusion is sufficient to drive extinction learning even in animals that had failed standard extinction training — a foundational finding linking neurotrophin-mediated synaptic plasticity directly to the core cognitive operation that trauma-focused psychological therapy is trying to engineer. Meanwhile NICE NG116 still places trauma-focused CBT and EMDR before any pharmacotherapy. So when search interest for peptides for PTSD, BDNF and fear extinction, synaptogenic agents for trauma and — specifically — Dihexa in the trauma context climbs, the question is real but the answer demands rigour. Could a synaptogenic HGF/c-Met peptide help PTSD or complex PTSD? This is the 2026 UK evidence review.

PTSD in the UK in 2026: Scale, Demographics & the Treatment Gap

The PTSD UK headline figure — that around 1 in 20 UK adults meet diagnostic criteria for PTSD at any one time — understates the true population trauma burden. Lifetime prevalence is considerably higher: by age 65 a substantial minority of UK adults will have met PTSD criteria at some point, even if remitted at survey. Women are roughly as likely as men to develop PTSD overall, but the trauma exposures differ: women are more likely to be exposed to interpersonal trauma (sexual violence, domestic abuse), while men are more likely to be exposed to combat, road traffic collisions and assault. Black, Asian and minority-ethnic adults in the UK have higher untreated rates relative to need; people from low-income backgrounds and people in contact with the criminal-justice system have substantially higher prevalence — the Karatzias et al. UK male prisoner study reported 7.7% PTSD and 16.7% complex PTSD in sentenced male prisoners.

Critically, only about a quarter of UK adults screening positive for PTSD are receiving evidence-based psychological treatment at any one time. The treatment gap is the dominant public-health problem — not the absence of effective therapies. NHS Talking Therapies for anxiety and depression (the service formerly known as IAPT) accepts adult self-referral in England, has integrated trauma-focused psychological therapy into its pathway, and reports recovery rates for PTSD that are broadly comparable to those for depression and anxiety. Combat Stress and Op COURAGE serve veterans. Mind, Rethink Mental Illness and PTSD UK sit alongside as third-sector resources.

The treatment gap is the gap into which interest in unlicensed neuroplasticity-targeted compounds — Dihexa, Semax, Selank and the broader nootropic landscape, cerebrolysin, psilocybin, MDMA, ketamine, ibogaine — flows. The same forces drive search interest for peptides for trauma, BDNF for fear extinction, Dihexa for PTSD and adjacent terms, and the same logic that applies on the depression review and the anxiety & chronic stress review applies here: real unmet need is not the same as evidence of efficacy.

The Biology of PTSD: Fear Circuit, Amygdala-vmPFC, Hippocampus, HPA Axis

Before asking whether Dihexa could plausibly help, it is worth being precise about what PTSD actually is at the level of neurocircuit and synapse. Six decades of trauma research have produced a remarkably consistent picture, and the 2012 review by Mahan & Ressler in Trends in Neurosciences remains the canonical synthesis.

Amygdala Hyperreactivity

The basolateral amygdala (BLA) is the principal site of Pavlovian fear conditioning. A neutral cue (the conditioned stimulus, CS) paired with an aversive event (the unconditioned stimulus, US) produces an associative fear memory that — in normal physiology — allows the organism to anticipate threat. In PTSD, amygdala hyperreactivity to trauma-associated cues and to non-specific threat-related stimuli is consistently documented on functional MRI. The hyperreactive amygdala drives the cardinal PTSD symptoms: intrusive memories, flashbacks, exaggerated startle response, hypervigilance, autonomic arousal and the trauma-related component of nightmares.

Within the BLA, fear memory formation depends on AMPA and NMDA glutamatergic transmission, on calcium-calmodulin kinase II (CaMKII) signalling, on the MAPK/ERK and PI3K pathways and on the trafficking of GluA1-containing AMPA receptors to the synapse — all of which are downstream of the same broad synaptic plasticity machinery that BDNF/TrkB and HGF/c-Met converge on.

The Ventromedial Prefrontal Cortex & Fear Extinction

The vmPFC — especially its rodent homologue, the infralimbic cortex (IL) — is the brain region most consistently implicated in the inhibitory extinction of conditioned fear. Successful extinction does not erase the original fear memory; it creates a competing inhibitory memory ("the CS no longer predicts the US") that, when retrieved, suppresses the amygdala-mediated fear response. The vmPFC sends GABAergic-mediated inhibitory input to the amygdala via intercalated cell masses; lesions to the vmPFC or to its projections produce extinction failure in animal models and exaggerated, persistent fear responses in humans.

PTSD has been usefully reframed as a disorder of impaired extinction. Patients with PTSD show reduced vmPFC activation on extinction-recall paradigms and reduced functional connectivity between the vmPFC and the amygdala compared with trauma-exposed controls without PTSD. The clinical implication is large: trauma-focused psychological therapies (TF-CBT, EMDR, prolonged exposure) are, mechanistically, extinction-learning protocols. If the underlying neurobiology of extinction is impaired, the therapy works less reliably. This is where a synaptic-plasticity intervention could, in principle, help — by lowering the synaptic barrier to extinction learning.

The Hippocampus & Contextual Discrimination

The hippocampus encodes the context of fear memories — the environmental information that distinguishes the dangerous situation from a safe one. PTSD is associated with reduced hippocampal volume on MRI; whether this is cause or consequence of trauma is still debated, but the Vietnam-era twin study (one twin combat-deployed, one not) suggests at least part of the reduced hippocampal volume is a pre-existing vulnerability rather than purely a consequence of trauma. Functionally, impaired hippocampal context-discrimination produces fear-response generalisation: the patient experiences fear-like responses in safe contexts that share peripheral features with the traumatic context. Reduced hippocampal BDNF is consistently reported in animal PTSD models; Peters et al.'s 2026 Neuroscience Bulletin review highlights H3K9me2-mediated suppression of hippocampal BDNF mRNA as one of the epigenetic mechanisms of impaired extinction.

The HPA Axis, Cortisol & Autonomic Dysregulation

PTSD shows a paradoxical HPA-axis profile: low baseline cortisol with enhanced glucocorticoid-receptor sensitivity and enhanced negative feedback. Sympathetic-nervous-system overactivation (high resting heart rate, blunted heart-rate-variability, elevated peripheral noradrenaline turnover) is consistent across studies and is the rationale behind both the locus-coeruleus-targeted prazosin literature for trauma nightmares and the stellate-ganglion-block-targeted sympathetic-modulation literature. None of this autonomic / endocrine biology is the obvious mechanistic target of a synaptogenic peptide — though the downstream consequences (allostatic load, chronic stress-mediated hippocampal atrophy) overlap with the BDNF/HGF story.

Memory Reconsolidation

A separate but related body of work concerns memory reconsolidation. When a consolidated long-term memory is retrieved it enters a temporarily labile state during which it can be disrupted, modified or strengthened before being re-stored. The pharmacological reconsolidation literature (propranolol; D-cycloserine for facilitation; protein-synthesis inhibitors in animals) is one of the most active areas of trauma neuroscience. The 2025 Peters et al. Neuroscience Bulletin review summarises the reconsolidation vs extinction debate and notes that reconsolidation-based approaches may produce more durable change than extinction-based exposure, though extinction-based protocols are more reliably deployable in routine clinical care. Whether a synaptogenic peptide modulates reconsolidation or only consolidation/extinction is an open question.

Where Does HGF/c-Met Sit in the Fear Circuit?

The HGF/c-Met system — hepatocyte growth factor and its receptor tyrosine kinase, c-Met — is expressed throughout the adult CNS, including in the amygdala, hippocampus and prefrontal cortex. In developmental neurobiology, HGF/c-Met regulates neuronal migration, axon guidance and synapse formation; in adult brain it sits within the same broad synaptic-plasticity machinery as BDNF/TrkB, glutamatergic AMPA throughput, mTORC1-mediated translation and dendritic-spine remodelling. The 2014 Benoist et al. paper demonstrated experimentally that the procognitive and synaptogenic effects of angiotensin IV-derived peptides (the family that includes Dihexa) require activation of the HGF/c-Met system. Block c-Met and the cognitive effects disappear. This is the strongest mechanistic anchor for the Dihexa-as-synaptogen claim.

For PTSD specifically, the relevant biology has two distinct strands. First, HGF/c-Met may modulate the extinction circuit directly through synaptic plasticity in vmPFC-amygdala connections. The literature here is preclinical and largely indirect: there is no published study of selective HGF/c-Met agonism on fear conditioning or fear extinction in any rigorous model. But the convergence of HGF/c-Met onto the same MAPK/ERK and PI3K-Akt-mTOR pathways that BDNF engages, and onto the same dendritic-spine actin-cytoskeleton remodelling machinery, makes the inference plausible.

Second — and more concretely — the broader brain renin-angiotensin system has been independently implicated in fear extinction. Marin et al. (Biological Psychiatry, 2014) showed that AT1R blockade enhances fear extinction in healthy adults, and the Khoury et al. 2012 retrospective in trauma-exposed Atlanta inner-city residents found that ACE-inhibitor or ARB use was associated with fewer PTSD symptoms. This is consistent with a broader picture in which angiotensin-derived signalling modulates fear circuit plasticity. Dihexa, derived from angiotensin IV, fits into this picture even though it is mechanistically distinct from AT1R blockade. The 2021 Limbic Neuropeptidergic Modulators of Emotion and Their Therapeutic Potential for Anxiety and Post-Traumatic Stress Disorder review (J Neurosci) places neuropeptide modulators of the amygdala fear circuit within a serious therapeutic-target framework.

The Peters et al. 2010 Science Paper: Why It Matters

The 2010 Peters et al. paper in Science remains the single most-cited foundational result in this field. The authors trained rats on fear conditioning, then attempted fear extinction. A subset of animals reliably failed to extinguish — the experimental model of treatment-resistant PTSD. Direct infusion of BDNF into the infralimbic cortex of those extinction-failure animals produced extinction-like reductions in fear responding without further extinction training. In other words: a neurotrophin, delivered to the right brain region, was sufficient to substitute for behavioural extinction training in animals that had not been able to learn extinction by behaviour alone.

This is the result that has driven the last fifteen years of interest in neurotrophin-based and synaptic-plasticity-based interventions for PTSD. It is the experimental proof of principle that "more synaptic plasticity in the right region" can do the cognitive work of trauma-focused therapy at the neural level. It is also the strongest theoretical anchor for the inference that a synaptogenic agent like Dihexa — if delivered to the right region at the right time — might lower the synaptic barrier to extinction in patients with PTSD who have failed standard extinction-based psychotherapy.

But Peters et al. used surgical microinfusion in rats. Dihexa is taken orally. The brain-region selectivity, dose-response relationship, time window for effect on extinction learning, and interaction with psychotherapy are completely unestablished in any human trial. The inferential gap between "infralimbic BDNF rescues extinction in rats" and "oral Dihexa helps PTSD patients" is enormous.

NICE NG116 & the Current UK Standard of Care for PTSD in 2026

NICE NG116 (Post-traumatic stress disorder) was published in December 2018 and remains, with subsequent surveillance updates, the controlling NHS guidance in 2026. The pathway it specifies is structured and unambiguous:

First-Line: Trauma-Focused CBT & EMDR

For adults with a diagnosis of PTSD more than one month after the trauma, NICE NG116 recommends individual trauma-focused cognitive behavioural therapy (TF-CBT) — including cognitive processing therapy (CPT), cognitive therapy for PTSD, narrative exposure therapy and prolonged exposure (PE) — as first-line treatment. Eye Movement Desensitisation and Reprocessing (EMDR) is recommended as an alternative first-line for adults whose trauma is not combat-related, with broadly equivalent evidence on outcome measures. NHS Talking Therapies for anxiety and depression in England now incorporate TF-CBT and EMDR pathways for PTSD as standard, and accept adult self-referral.

Drug treatments — sertraline, paroxetine, venlafaxine — are not recommended as routine first-line treatment in preference to trauma-focused psychological therapy. They sit as second-line, augmentation or alternative where the patient cannot or will not engage with trauma-focused therapy. Prazosin is used off-label for trauma-associated nightmares; the evidence base is mixed but it is widely deployed in specialist clinics.

Children & Adolescents

For children and young people aged 7-17 years, NICE NG116 recommends TF-CBT as first-line, with EMDR as an option for those who do not respond. Drug treatments are not recommended for children with PTSD as a first-line option.

Acute Stress Disorder & Prevention

NICE NG116 advises against routine post-trauma debriefing for everyone — the Cochrane evidence does not support universal post-trauma psychological debriefing and may even worsen outcomes in some adults. For people with acute stress symptoms in the first month, watchful waiting and individualised TF-CBT for those whose symptoms persist or are severe is the recommended approach.

Complex PTSD

For people with complex presentations — multiple, prolonged or developmental trauma — NICE NG116 recommends extending the duration of trauma-focused psychological therapy and considering preparatory stabilisation work where indicated. NHS specialist trauma services (e.g. the Traumatic Stress Clinic at the Camden & Islington NHS Foundation Trust), the Maudsley centre for anxiety disorders, and Scotland's Rivers Centre operate phase-based pathways for ICD-11 complex PTSD.

None of this guidance mentions Dihexa, fosgonimeton, angiotensin IV peptides or any synaptic-plasticity-targeted research peptide. The evidence base required to move into NICE recommendation is large multi-site Phase 3 trial data — which does not exist for any HGF/c-Met agent in PTSD.

Beyond NG116: New PTSD Pharmacology in 2026

The PTSD pharmacology landscape has been more active in the last five years than in the previous two decades. Several distinct therapeutic strategies are now in late-stage clinical development or regulatory review.

MDMA-Assisted Therapy

MDMA-assisted therapy — two or three sessions of MDMA (typically 80-180 mg) combined with extended sessions of trauma-focused psychotherapy — is the most prominent psychedelic-adjacent intervention for PTSD. The 2021 Mitchell et al. Nature Medicine Phase 3 trial (MAPP1) reported that 67% of severe-PTSD participants no longer met diagnostic criteria after three MDMA-assisted sessions, versus 32% on inactive placebo with the same psychotherapy. MAPP2 (2023), the confirmatory Phase 3 in moderate-to-severe PTSD, reported similarly large effect sizes.

In January 2022 the MHRA awarded MAPS (now Lykos Therapeutics) an Innovation Passport for MDMA-assisted therapy for PTSD — the entry point to the UK Innovative Licensing and Access Pathway (ILAP). In August 2024 the FDA declined to approve Lykos' MDMA-assisted therapy submission, citing data-integrity, methodology and post-trial-functional-unblinding concerns, and asked for an additional Phase 3 study. The Forces in Mind Trust and King's College London-led trial of MDMA-assisted therapy in UK veterans with treatment-resistant PTSD reported initial safety data in 2023-2024.

As of 2026, MDMA-assisted therapy in the UK is accessible only through clinical trials or specialist research settings. NHS Op COURAGE and NHS Talking Therapies do not provide it. The mechanism is plausibly synergistic with the BDNF/HGF synaptic plasticity story: MDMA produces a transient state of reduced amygdala-mediated threat response and enhanced prosocial / introspective access, during which trauma-focused psychotherapy may engage extinction-learning circuitry more effectively. This is mechanistically close to the "lower the barrier to extinction" framing that motivates synaptogenic-peptide interest.

Ketamine & Esketamine

Ketamine (typically intravenous racemic ketamine, 0.5 mg/kg infused over 40 minutes) has accumulated multiple positive RCTs in PTSD. The Feder et al. 2021 American Journal of Psychiatry trial compared six infusions of ketamine to six infusions of midazolam (active placebo) over two weeks in chronic PTSD and reported significantly greater CAPS-5 reductions in the ketamine arm. Intranasal esketamine (Spravato) is licensed in the UK by the MHRA for treatment-resistant depression but not for PTSD. Compounded racemic ketamine for PTSD is generally accessed through private clinics or research protocols. NICE NG116 does not recommend ketamine for PTSD.

Mechanistically, ketamine produces rapid mTORC1-mediated synaptogenesis in the prefrontal cortex through NMDA antagonism, AMPA throughput and a downstream BDNF release. This is the same synaptic-plasticity space the Dihexa interest occupies — though Dihexa's claimed mechanism (HGF/c-Met-mediated dendritic-spine formation) is upstream-different from ketamine's NMDA-dissociation entry point.

Stellate Ganglion Block (SGB)

Stellate ganglion block — ultrasound-guided injection of local anaesthetic (typically bupivacaine or ropivacaine) into the cervical sympathetic chain — has been investigated for PTSD on the rationale that PTSD involves chronic sympathetic hyperarousal. The 2025 systematic review and meta-analysis in Autonomic Neuroscience pooled three controlled trials and reported a pooled CAPS reduction of approximately 6.24 points compared with control, with substantial heterogeneity and a small number of high-quality RCTs. A larger US Department of Veterans Affairs multisite RCT is now under way.

SGB is not in NICE NG116. In the UK it is accessed primarily through specialist pain-medicine clinics or research protocols. It is not a synaptic-plasticity intervention and is mechanistically distinct from any plausible Dihexa pathway.

Brexpiprazole + Sertraline (Rexulti combo)

Otsuka and Lundbeck's brexpiprazole-plus-sertraline combination for PTSD was submitted to the US FDA in 2024 on the basis of three Phase 3 trials showing modest CAPS reductions over sertraline monotherapy. The combination is not currently licensed in the UK for PTSD. Its mechanism is dopamine partial-agonism plus 5-HT2A antagonism plus serotonergic reuptake inhibition — squarely in the monoaminergic-modulation family, distinct from any synaptic-plasticity-direct mechanism.

Psilocybin & Other Psychedelics

Psilocybin-assisted therapy is being trialled in PTSD (notably the COMPASS Pathways and Usona Institute programmes), though most current Phase 3 work is for treatment-resistant depression. COMPASS Pathways's UK-headquartered programme is one of the most prominent in the world. The MHRA has not licensed psilocybin for any indication in 2026.

2026 News Context: What Has Just Changed in the PTSD Landscape

Several developments in the trauma field over the last 18 months are directly relevant context for how to think about a synaptogenic peptide in PTSD.

1. The August 2024 FDA Lykos / MDMA decision. The FDA's Complete Response Letter requesting an additional Phase 3 study delayed MDMA-assisted therapy by several years in the United States and has knock-on implications for the UK ILAP pathway. The MAPS / Lykos UK Innovation Passport is still active but no MHRA submission has been filed in 2026.

2. The 2024 Op COURAGE evaluation. The Murthy et al. evaluation of the NHS England Op COURAGE High Intensity Service reported that 96% of participants rated the service positively and that there were clinically significant reductions in depression, anxiety and PTSD symptoms at programme exit. This is one of the strongest pieces of evidence that the NICE-recommended trauma-focused psychological therapy pathway, when delivered well at scale, produces meaningful outcomes. It is also the strongest counter-argument to the ‘NHS care doesn’t work, I need an unlicensed peptide’ framing that often appears in nootropic-community discussions of PTSD.

3. The 2025 KCMHR longitudinal update. The King's Centre for Military Health Research has continued to report on the long-term cohort of UK military personnel deployed to Iraq and Afghanistan. The headline figures — 7.4% PTSD overall, 17% for combat-deployed veterans, persistently elevated common mental disorder rates over a decade post-deployment — have stabilised but not improved. The KCMHR Evidence Fact Sheet is the canonical UK military mental-health reference.

4. The 2025 CPTSD prevalence meta-analysis. The Psychiatry Research meta-analysis of 167 studies and 138,681 participants put global pooled CPTSD prevalence at 6.2%, with up to 12.4% in community samples and 44.7% in clinical samples. This is the strongest single dataset showing that ICD-11 complex PTSD is a meaningful, prevalent, distinct clinical entity, and that any pharmacological intervention — including a hypothetical synaptogenic peptide — will need to be evaluated against this newer, more demanding clinical category.

5. The 2025 SGB meta-analysis. The Autonomic Neuroscience pooled meta-analysis placed stellate ganglion block in the ‘plausible but underpowered’ bucket. The next-generation multisite RCT is now recruiting in the US Department of Veterans Affairs system, with a planned UK collaborative component.

6. The 2025-2026 fear-extinction literature. The 2026 Neuroscience Bulletin review by Peters et al. on biomarkers and new treatments for PTSD and the 2025 Neuroscience Bulletin review on memory reconsolidation vs extinction have collectively re-centred the BDNF / infralimbic synaptic plasticity story in PTSD. The molecular focus has shifted further into the epigenetic regulation of hippocampal BDNF, the H3K9me2 / G9a axis and the ERK / mTORC1 downstream pathway — the same downstream synaptic plasticity machinery that HGF/c-Met activates.

7. The 2025 Frontiers fear-memory-erasure review. The Frontiers in Neurology review on advances in fear memory erasure summarises the mechanistic case for combining behavioural extinction protocols with synaptic-plasticity-enhancing pharmacology — the precise space in which Dihexa would, in theory, sit.

Dihexa Specifically in PTSD: What the Evidence Actually Is

To be direct about it: there is no published controlled clinical trial of Dihexa (PNB-0408) in PTSD, complex PTSD, acute stress disorder, treatment-resistant PTSD or moral injury. No registered Phase 1, 2 or 3 trial. No case series. No registry. The closest clinical-stage relative is fosgonimeton (ATH-1017), a phosphate prodrug of dihexa developed by Athira Pharma; fosgonimeton was wound down after the LIFT-AD Phase 2/3 readout in Alzheimer's and never entered PTSD-specific trials — see the fosgonimeton review for full context.

The evidence base for thinking about Dihexa in PTSD therefore consists of:

Preclinical Dihexa Cognitive Data

The Wright laboratory at Washington State University and collaborating groups published the foundational preclinical cognitive-enhancement data on Dihexa in the 2008-2015 period. Wright & Harding (Neuroscience, 2015) is the consolidated review. The findings are that oral Dihexa crosses the blood-brain barrier, that it produces measurable synaptogenesis in hippocampal preparations at extraordinarily low concentrations, and that it improves performance on spatial working memory and passive-avoidance tasks in aged rats and in scopolamine- or aluminium-impaired rats. The 2014 Benoist et al. paper demonstrated that the cognitive effects of angiotensin IV-derived peptides require activation of the HGF/c-Met system.

None of this work used fear-conditioning or fear-extinction paradigms. None measured amygdala or vmPFC plasticity directly. None modelled PTSD. The cognitive endpoints (spatial working memory, passive avoidance) overlap somewhat with the contextual-memory dimension of PTSD biology but do not directly probe the fear-circuit machinery that PTSD pharmacology must engage.

Renin-Angiotensin Pathway & Fear Extinction

The closest indirect evidence for any angiotensin-related modulation of fear extinction is the AT1R-blockade literature. The Marin et al. 2014 Biological Psychiatry trial showed that the angiotensin-receptor blocker losartan enhances fear extinction in healthy adults on a behavioural conditioning task. The Khoury et al. 2012 study in Atlanta inner-city trauma-exposed adults found that ACE-inhibitor or ARB use was associated with fewer PTSD symptoms in a retrospective analysis.

Crucially, AT1R blockade and HGF/c-Met agonism are mechanistically distinct, and Dihexa is not an AT1R blocker. The angiotensin-IV / AT4 family of which Dihexa is part operates downstream of HGF/c-Met, not through classical AT1R signalling. So the AT1R-blockade fear-extinction story is suggestive of broader angiotensin-system involvement in fear circuit modulation but does not directly support Dihexa specifically.

BDNF / HGF Convergence onto the Same Plasticity Machinery

The most coherent inferential argument for Dihexa in PTSD remains: (a) the Peters 2010 Science paper showed infralimbic BDNF infusion produces fear extinction in extinction-failure rats; (b) HGF/c-Met converges on the same downstream synaptic plasticity machinery as BDNF/TrkB — PI3K-Akt-mTORC1, MAPK/ERK, AMPA-receptor trafficking, dendritic-spine remodelling; (c) Dihexa is a positive modulator of HGF/c-Met; therefore (d) Dihexa might lower the synaptic barrier to extinction learning in PTSD. The logic is reasonable. The empirical demonstration of the final step is, in 2026, zero.

This is the same mechanistic-plausibility-without-clinical-evidence pattern that recurs across this site — from the TBI & concussion review to the depression review to the anxiety & chronic stress review — and the same intellectual discipline applies: a coherent mechanism is necessary but not sufficient. Clinical trial data is the only thing that closes the gap.

Safety: PTSD-Specific Polypharmacy & Drug-Interaction Concerns

If, in spite of all of the above, a person with PTSD considers self-administering Dihexa, the safety concerns are not just those covered on the general side effects page. PTSD-specific polypharmacy adds several distinct interaction concerns.

SSRI / SNRI Co-Administration

Many PTSD patients are prescribed sertraline, paroxetine or venlafaxine. There is no human pharmacokinetic interaction study of Dihexa with any SSRI or SNRI. The serotonin-system-direct mechanism of SSRIs and the synaptogenic mechanism of Dihexa are not predicted to interact pharmacodynamically in a clinically significant way, but the absence of any direct study means ‘not predicted’ is the strongest statement possible. Co-administration is genuinely uncharacterised.

Benzodiazepines & Prazosin

Long-term benzodiazepine use is common in PTSD despite NICE recommendation against it. Prazosin is widely deployed off-label for trauma nightmares. Neither has any known interaction with Dihexa, but again the empirical evidence is zero.

Psychedelic-Assisted Therapy

Anyone enrolled in or considering MDMA-, ketamine- or psilocybin-assisted therapy should not simultaneously self-administer an unlicensed research peptide that engages the same synaptic-plasticity space. The biological rationale for the trial is the targeted synaptic-plasticity intervention; introducing an uncharacterised second synaptic-plasticity-modulating agent confounds the trial protocol, may breach informed-consent obligations, and may produce additive or interactive effects that nobody — trial investigators included — can predict.

Psychotherapy & Extinction-Learning Windows

The deeper conceptual safety concern is that PTSD treatment is fundamentally an active engagement with traumatic memory — in extinction, in reconsolidation, in cognitive restructuring, in EMDR's bilateral-stimulation framework. Pharmacologically biasing the synaptic-plasticity substrate of that active engagement — with an unlicensed, uncharacterised agent, outside of trial supervision — risks distorting the trauma-processing window in unpredictable ways. The Peters 2010 result is striking precisely because infralimbic BDNF in the right place at the right time substitutes for behavioural extinction; the corollary is that the same biology in the wrong place at the wrong time could plausibly impede or distort extinction. There is no empirical evidence that Dihexa does either — but the absence of evidence here is not reassuring.

PTSD in High-Risk UK Occupations: Veterans, Emergency Services, NHS Staff

Certain UK occupational groups carry disproportionate PTSD burden.

UK Veterans

The KCMHR longitudinal cohort remains the canonical UK military mental-health dataset. PTSD prevalence is approximately 7.4% in serving and ex-serving personnel overall, rising to 17% among those deployed in a combat role. Op COURAGE in England, with devolved equivalents in Scotland (Veterans First Point), Wales (Veterans NHS Wales) and Northern Ireland, provides the integrated NHS pathway. Combat Stress (24-hour helpline 0800 138 1619) provides veteran-specialist mental-health care alongside.

Police, Fire, Ambulance & Search-and-Rescue

UK emergency-services personnel carry PTSD rates broadly comparable to veterans. The Police Federation surveys have consistently reported elevated probable-PTSD rates in serving officers; ambulance and fire-service surveys are similar. Most NHS Trusts have specialist occupational-health pathways for emergency-services personnel, and the Mind Blue Light Programme has been the third-sector pillar.

NHS Staff

The COVID-19 pandemic added a substantial PTSD layer to UK NHS staff. The BMJ and Lancet Psychiatry have published multiple prevalence studies of probable PTSD in NHS frontline staff during and after the acute pandemic phase, with rates considerably above pre-pandemic baselines. NHS Practitioner Health and the Hospital Consultants & Specialists Association have integrated trauma-focused care into staff-support pathways.

Survivors of Domestic Abuse, Sexual Violence & Modern Slavery

Survivors of intimate-partner violence, sexual assault, modern slavery, trafficking and prolonged interpersonal trauma carry the highest rates of complex PTSD on community-sample data. UK specialist NHS trauma services, the Rape Crisis England & Wales federation, Women's Aid, and the Survivors UK and Survivors Trust networks provide the third-sector pathway. The 2021 Karatzias et al. UK prison study highlights the overlap between developmental-trauma populations and criminal-justice-system contact.

Practical Realities: What Actually Works for PTSD in 2026

This is the section that, if a single person reads this article and applies one thing, matters most. The evidence-based interventions for PTSD that demonstrably work, in order of evidence strength, are:

1. Trauma-focused cognitive behavioural therapy (TF-CBT). Cognitive Processing Therapy, Prolonged Exposure, Cognitive Therapy for PTSD and narrative-exposure-therapy variants all have substantial RCT-evidence bases. NHS Talking Therapies in England accepts adult self-referral. Recovery rates are meaningful, typically 50-65% achieving clinically significant improvement in single-event PTSD; lower but still substantial in complex presentations.

2. Eye Movement Desensitisation and Reprocessing (EMDR). Broadly equivalent first-line evidence to TF-CBT on the major NICE-cited meta-analyses. The proposed mechanism (bilateral stimulation reducing working-memory bandwidth during trauma recall) is debated but the outcome data are real.

3. Licensed pharmacotherapy. Sertraline, paroxetine, venlafaxine as second-line. Prazosin off-label for trauma nightmares. Effect sizes are smaller than for psychotherapy and benefit usually requires 6-12 weeks of consistent treatment.

4. Specialist NHS or veterans' service referral. For complex PTSD, treatment-resistant PTSD, polytraumatic presentations or moral-injury overlap, specialist NHS trauma clinics, Op COURAGE, Combat Stress and the Maudsley centre for anxiety disorders offer phase-based or extended-duration trauma-focused therapy that primary-care or community-mental-health-team-level provision generally cannot.

5. Clinical-trial enrolment. The NIHR Be Part of Research portal lists UK PTSD trials. Specific programmes worth investigating include the King's College London / Forces in Mind Trust MDMA programme, the COMPASS Pathways psilocybin programme (currently focused on depression), and the various ketamine and SGB trials. Clinical-trial enrolment provides protocol-supervised access to investigational treatments with full safety monitoring.

6. Lifestyle, sleep and the modifiable substrate. Sleep dysregulation is one of the most consistent PTSD symptoms (see the sleep & memory consolidation review) and is also one of the strongest contributors to symptom maintenance: poor sleep impairs the very fear-extinction learning that trauma-focused therapy depends on. Structured exercise raises BDNF and reduces PTSD symptom severity in multiple RCTs. Reducing alcohol and recreational-substance use is consistently associated with better PTSD outcomes. None of this is exciting, none of it requires an unlicensed peptide, all of it actually works.

7. Then — if at all — unlicensed peptides. The position this site has consistently taken: clinical trial participation always preferable to self-experimentation; if self-experimentation is going to happen anyway, please read the UK research-chemical legal status page, the side effects page and the dosage page; and do not do this while acutely symptomatic from severe PTSD without specialist input.

What Would Need to Happen for Dihexa to Become a Real PTSD Option?

For Dihexa — or any HGF/c-Met agonist — to move from ‘mechanistically interesting’ to ‘evidence-based PTSD intervention’, the following clinical-translation steps are required, in roughly this order:

1. Fear-conditioning / fear-extinction animal data with Dihexa. Published, replicated, in a recognised PTSD-relevant model (typically rat or mouse auditory fear conditioning with extinction-recall paradigms, or single-prolonged-stress models). The Peters-style experimental result for Dihexa specifically has, to date, not been published.

2. Phase 1 PTSD-population pharmacokinetic / pharmacodynamic data. The Phase 1 work done on dihexa and on fosgonimeton was in healthy volunteers and Alzheimer's-disease populations. PTSD-population pharmacokinetics, biomarker engagement and target-engagement imaging (vmPFC connectivity, fear-extinction-paradigm fMRI) are not yet published.

3. Phase 2a proof-of-concept trial. A small, randomised, placebo-controlled trial in PTSD patients — ideally combined with structured trauma-focused psychotherapy — with CAPS-5 as primary outcome and amygdala-vmPFC functional connectivity as a key secondary biomarker endpoint.

4. Phase 3 confirmatory trial. Multi-site, sufficiently powered, with active-comparator (TF-CBT or sertraline) arm. NICE NG116 update would require this scale of evidence.

5. MHRA & NICE evaluation. Following the Innovation Passport / Innovative Licensing and Access Pathway template that MAPS / Lykos used for MDMA-assisted therapy.

The optimistic timeline for this sequence, if a serious sponsor decided to start tomorrow, is around 8-10 years to a positive Phase 3 readout. The realistic timeline, given the Athira Pharma wind-down of fosgonimeton and the absence of any other commercial HGF/c-Met agent in clinical development for PTSD specifically, is that this trial sequence is unlikely to happen at all without a fresh sponsor stepping in. The closest commercial-grade HGF/c-Met clinical-stage programme remains fosgonimeton (ATH-1017), which never entered PTSD trials.

The Bottom Line: A Real Mechanism, a Real Disorder, and Zero Human Dihexa Data

This is the editorial position of this page, stated as plainly as we can manage:

PTSD is a serious, prevalent, treatable disorder. Around 4.4% of UK adults meet PTSD criteria at any one time; complex PTSD adds a further 6-12% layer at the community level. The neuroscience is unusually well-developed: the amygdala-vmPFC fear-extinction model is among the most-replicated neurocircuit accounts in psychiatry, and the Peters 2010 demonstration that infralimbic BDNF is sufficient to drive extinction in extinction-failure animals is one of the strongest single mechanistic results in trauma neuroscience.

Dihexa — via HGF/c-Met — engages the same broad synaptic-plasticity machinery that BDNF engages. The mechanistic case for Dihexa in PTSD is therefore at least as coherent as it is for the depression, anxiety, TBI and MCI reviews, and arguably more so because PTSD has a single dominant neurocircuit that synaptic plasticity is the explicit therapeutic substrate of.

But: zero human trial data. Not one Phase 1, 2 or 3 trial of Dihexa, fosgonimeton or any angiotensin IV-derived synaptogenic peptide in PTSD. NICE NG116 still puts trauma-focused CBT and EMDR first and works for most patients. MDMA-assisted therapy holds an MHRA Innovation Passport but is not yet licensed. Ketamine and esketamine work in a related synaptic-plasticity space but neither is licensed for PTSD in the UK. Stellate ganglion block has promising but preliminary meta-analytic data.

The honest 2026 answer for PTSD is: trauma-focused psychological therapy first, licensed pharmacotherapy second, specialist clinic or clinical-trial enrolment third, lifestyle modifiable substrate alongside all of those, and unlicensed research peptides last — if at all, and definitely not while acutely symptomatic without specialist input. The mechanism is real. The disorder is real. The evidence for Dihexa specifically is, in 2026, zero.

Frequently Asked Questions: Dihexa & PTSD

Can Dihexa help PTSD or complex PTSD?

There is no published controlled clinical trial of Dihexa in PTSD, complex PTSD, acute stress disorder, treatment-resistant PTSD or moral injury. The mechanistic case is partially coherent: PTSD involves impaired vmPFC-mediated fear extinction, the Peters 2010 Science paper showed infralimbic BDNF infusion produces extinction in extinction-failure animals, and Dihexa engages the same broad synaptic-plasticity machinery via HGF/c-Met. But the human evidence is zero, and self-experimenting with an unlicensed research peptide while acutely symptomatic is not a sensible plan.

Is there any direct evidence that Dihexa modulates fear extinction?

Not directly. The preclinical Dihexa literature used spatial-working-memory and passive-avoidance cognitive tasks, not fear-conditioning or fear-extinction paradigms. The closest indirect evidence is the AT1R-blockade fear-extinction literature (Marin et al. 2014) and the Benoist 2014 demonstration that the cognitive effects of angiotensin-IV peptides require HGF/c-Met activation. Inference, not demonstration.

What does NICE NG116 say about pharmacology for PTSD?

NICE NG116 says drug treatment should not be used as routine first-line in preference to trauma-focused psychological therapy. Second-line options are sertraline, paroxetine and venlafaxine. Prazosin is used off-label for trauma nightmares. Dihexa is not mentioned anywhere in NG116.

Is MDMA-assisted therapy available on the NHS?

No. MDMA-assisted therapy holds an MHRA Innovation Passport in the UK but is not licensed. The FDA declined approval in August 2024. UK access in 2026 is through clinical trials only.

What about ketamine for PTSD on the NHS?

Esketamine (Spravato) is licensed by the MHRA only for treatment-resistant depression, not PTSD. Racemic ketamine for PTSD is generally accessed through private clinics or research protocols. NICE NG116 does not recommend ketamine for PTSD.

Where can I find PTSD support in the UK?

NHS Talking Therapies for anxiety and depression accepts adult self-referral in England. Op COURAGE serves veterans. Combat Stress provides veterans' specialist services (24-hour helpline 0800 138 1619). PTSD UK, Mind, Rape Crisis England & Wales, Women's Aid and Survivors Trust sit alongside as third-sector resources. In immediate crisis, the Samaritans (24-hour, 116 123) or 999.

Sources & Citations

• NICE NG116. Post-traumatic stress disorder: recognising, assessing and treating PTSD in children, young people and adults.
• PTSD UK. UK PTSD prevalence statistics and demographics.
• PTSD UK. NICE guidelines in the UK for PTSD — plain-English summary.
• NHS England. NHS launches Op COURAGE veterans' mental health service.
• Murthy N et al. Evaluation of the NHS England Op COURAGE High Intensity Service for military veterans with significant mental health problems. BMC Psychiatry (2024).
• King's Centre for Military Health Research — Evidence Fact Sheet on UK military mental health.
• Stevelink SAM et al. Mental health outcomes at the end of the British involvement in the Iraq and Afghanistan conflicts: a cohort study (KCMHR).
• Karatzias T et al. PTSD and complex PTSD in sentenced male prisoners in the UK: prevalence, trauma antecedents, and psychiatric comorbidities. Psychological Medicine (2021).
• Prevalence of Complex Post-Traumatic Stress Disorder (CPTSD): A Systematic Review and Meta-Analysis. Psychiatry Research (2025).
• Peters J, Dieppa-Perea LM, Melendez LM, Quirk GJ. Induction of fear extinction with hippocampal-infralimbic BDNF. Science (2010).
• Mahan AL & Ressler KJ. Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder. Trends in Neurosciences (2012).
• Peters R et al. From Biomarkers to New Treatments for Post-Traumatic Stress Disorder. Neuroscience Bulletin (2026).
• Peters JL et al. How Fear Memory is Updated: From Reconsolidation to Extinction? Neuroscience Bulletin (2025).
• Advances in fear memory erasure and its neural mechanisms. Frontiers in Neurology (2024).
• Limbic Neuropeptidergic Modulators of Emotion and Their Therapeutic Potential for Anxiety and Post-Traumatic Stress Disorder. Journal of Neuroscience (2021).
• Marin MF et al. Angiotensin type 1 receptor inhibition enhances the extinction of fear memory. Biological Psychiatry (2014).
• Khoury NM et al. The Renin-Angiotensin Pathway in Posttraumatic Stress Disorder. Journal of Clinical Psychiatry (2012).
• Wright JW & Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Neuroscience (2015).
• Benoist CC et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the HGF/c-Met system.
• Mitchell JM et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine (2021).
• Mitchell JM et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine (2023).
• MAPS. Innovation Passport for MDMA as an adjunct to therapy for PTSD — UK MHRA / ILAP.
• Forces in Mind Trust. MDMA-assisted therapy for UK veterans with treatment-resistant PTSD — updates.
• King's College London. Pioneering trial of MDMA treatment for veterans with PTSD.
• Feder A et al. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder.
• Stellate ganglion blockade for the treatment of post-traumatic stress disorder: A systematic review and meta-analysis. Autonomic Neuroscience (2025).
• Combat Stress (24-hour helpline 0800 138 1619).
• Samaritans (free 24-hour helpline 116 123).
• Mind. PTSD and complex PTSD information.
• Rape Crisis England & Wales.
• NIHR Be Part of Research portal.